Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings

Core Insights - Axsome Therapeutics reported a revenue of $196 million for the quarter ended December 2025, marking a 65% increase year-over-year and exceeding the Zacks Consensus Estimate of $193.01 million by 1.55% [1] - The company's earnings per share (EPS) was -$0.71, an improvement from -$0.96 in the same quarter last year, although it fell short of the consensus estimate of -$0.70 by 1% [1] Revenue Breakdown - Product sales, net reached $194.7 million, surpassing the average analyst estimate of $191.25 million, reflecting a 66% increase compared to the previous year [4] - Royalty and milestone revenue was reported at $1.3 million, slightly above the average estimate of $1.18 million, but this represented a year-over-year decline of 9.5% [4] - Specific product sales included SYMBRAVO at $4.1 million (below the estimate of $5.27 million), Auvelity at $155.1 million (above the estimate of $151.25 million), and Sunosi at $36.7 million (exceeding the estimate of $33.86 million) [4] Stock Performance - Over the past month, Axsome's shares have returned -1.2%, contrasting with a +1.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]